基因疗法开发商SpliceBio获得1.35亿美元B轮融资，支持主要项目SB-007在Stargardt病中的1/2期临床开发-动脉网

EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio

CISION 等信源发布 2025-06-11 16:08



可切换为仅中文







Financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors

融资由EQT生命科学和赛诺菲风险投资共同牵头，罗氏风险基金参与，以及所有现有投资者跟投。

Proceeds will support the Phase 1/2 clinical development of lead program SB-007 in Stargardt disease, a genetic eye disorder that causes progressive vision loss and blindness

收益将用于支持领先项目SB-007在斯塔加特病（一种导致视力逐渐丧失和失明的遗传性眼病）的1/2期临床开发。

Funding will also advance a broader pipeline of genetic medicines targeting indications in ophthalmology, neurology, and other therapeutic areas

资金还将推动针对眼科、神经科和其他治疗领域适应症的更广泛的基因药物管道的发展。

STOCKHOLM

斯德哥尔摩

，

June 11, 2025

2025年6月11日

/PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in SpliceBio. The Spanish biotech company is developing novel therapies for genetic diseases – including ophthalmology, neurology, and other therapeutic areas – by leveraging an innovative intein platform. The platform allows large genes to be split into smaller pieces, delivered separately, and then reassembled to create full-length proteins needed to treat diseases..

/PRNewswire/ -- EQT生命科学公司欣然宣布，LSP 7基金已投资于SpliceBio。这家西班牙生物技术公司正在利用一种创新的内含肽平台，开发针对遗传病（包括眼科、神经科及其他治疗领域）的新型疗法。该平台可将大基因拆分为较小片段，分别递送后再重新组装，生成治疗疾病所需的全长蛋白质。

The

USD 135 million

1.35亿美元

Series B financing round will help fund the Phase 1/2 clinical trial of SpliceBio's lead gene therapy candidate, SB-007, which is being developed to treat Stargardt disease. The round was co-led by EQT Life Sciences and Sanofi Ventures, with participation from new investor Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners..

B轮融资将帮助资助SpliceBio主导基因疗法候选药物SB-007的1/2期临床试验，该药物正在开发用于治疗斯塔加特病。本轮融资由EQT生命科学和赛诺菲风险投资共同领投，新投资者罗氏风险基金以及所有现有投资者：新企业联合公司、UCB风险投资、Ysios资本、Gilde医疗保健、诺华风险基金和Asabys合伙人参与其中。

Stargardt disease, which leads to progressive vision loss and blindness, is the most commonly inherited condition causing degeneration in the macula, affecting 1 in 8,000-10,000 people. Currently, there are no approved treatments available for Stargardt disease. The disease is caused by mutations in the ABCA4 gene, which result in a dysfunctional ABCA4 protein.

Stargardt病是一种导致进行性视力丧失和失明的疾病，是最常见的遗传性黄斑变性疾病，每8,000至10,000人中就有1人受到影响。目前，尚无获批的Stargardt病治疗方法。该疾病由ABCA4基因突变引起，这些突变导致ABCA4蛋白功能异常。

SpliceBio's SB-007 uses an innovative Protein Splicing technology, based on a family of proprietary engineered proteins called inteins, originally developed at .

SpliceBio的SB-007使用了一种创新的蛋白质剪接技术，该技术基于一种称为内含肽的专有工程蛋白家族，最初开发于。

Princeton University

普林斯顿大学

. The approach overcomes the challenge of the ABCA4 gene that is too big for traditional gene therapy delivery methods, thereby enabling the production of a healthy ABCA4 protein directly in the retina.

这种方法克服了ABCA4基因过大而无法使用传统基因治疗方法的挑战，从而能够在视网膜内直接产生健康的ABCA4蛋白。

This approach has the potential to benefit the entire addressable patient pool, regardless of which of the more than 1,200 known mutations responsible for causing Stargardt disease patients carry. Crucially, the difficulty of delivering large genes is also a common barrier in treating many other genetic disorders, highlighting the broad potential and versatility of SpliceBio's technology beyond Stargardt disease..

这种方法有可能使整个可治疗的患者群体受益，无论患者携带的是导致斯塔加特病的1200多种已知突变中的哪一种。重要的是，递送大基因的困难也是治疗许多其他遗传疾病时常见的障碍，这突显了SpliceBio技术在斯塔加特病之外的广泛潜力和多功能性。

'This financing marks a pivotal milestone for SpliceBio as we advance the clinical development of SB-007 for Stargardt disease and continue to expand our pipeline across ophthalmology, neurology, and beyond,' said Miquel Vila-Perelló, Chief Executive Officer and Co-Founder of SpliceBio. 'The support from such high-quality investors underscores the strength of our programs and our unique Protein Splicing platform and its potential to unlock gene therapies for diseases that remain untreatable today.

“这一融资标志着SpliceBio的一个关键里程碑，因为我们正在推进SB-007针对斯塔加特病的临床开发，并继续在眼科、神经科及其他领域扩展我们的产品线，”SpliceBio首席执行官兼联合创始人米格尔·维拉-佩雷洛表示。“来自这些高质量投资者的支持凸显了我们项目的力量以及我们独特的蛋白质剪接平台的潜力，它有望为当今尚无法治疗的疾病解锁基因疗法。”

We are building a company positioned to lead the next wave of genetic medicines.'.

我们正在建立一家定位为引领下一波基因药物浪潮的公司。

Daniela Begolo

丹妮拉·贝戈洛

, Managing Director at EQT Life Sciences who will join the SpliceBio Board of Directors, commented: 'We are proud to support SpliceBio, a pioneer among the next generation of genetic medicine companies. Its Protein Splicing platform offers a novel solution to deliver large genes, one of the field's most pressing challenges, and exemplifies our commitment to backing science that transforms patients' lives.'.

EQT生命科学公司的董事总经理，将加入SpliceBio董事会，评论道：“我们很自豪能够支持SpliceBio，这是一家属于下一代基因医药公司的先驱。其蛋白质剪接平台提供了一种新颖的解决方案，可以递送大型基因，这是该领域最紧迫的挑战之一，并且体现了我们支持能够改变患者生活的科学的决心。”

Contact

联系

EQT Press Office,

EQT新闻办公室，

press@eqtpartners.com

This information was brought to you by Cision

此信息由Cision提供给您

http://news.cision.com

https://news.cision.com/eqt/r/eqt-life-sciences-co-leads-usd-135-million-series-b-financing-in-splicebio,c4162695

The following files are available for download:

以下文件可供下载：